Search results
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q3 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 5 months agoBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q3 2023 Earnings Call Transcript November 14, 2023...
We Think Brainstorm Cell Therapeutics (NASDAQ:BCLI) Needs To Drive Business Growth Carefully
Simply Wall St. via Yahoo Finance· 2 years agoThere's no doubt that money can be made by owning shares of unprofitable businesses. For example,...
While institutions own 23% of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI), retail investors are...
Simply Wall St. via Yahoo Finance· 11 months agoKey Insights Brainstorm Cell Therapeutics' significant retail investors ownership suggests that the...
Brainstorm Cell Therapeutics Inc.'s (NASDAQ:BCLI) Path To Profitability
Simply Wall St. via Yahoo Finance· 7 months agoBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) is possibly approaching a major achievement in its...
FDA Refuses To Accept BrainStorm Cell's Lead Candidate For Amyotrophic Lateral Sclerosis
Benzinga via Yahoo Finance· 1 year agoBrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) received a refusal to file letter from the FDA...
BrainStorm, after setbacks, withdraws approval application for ALS drug
BioPharma Dive via Yahoo Finance· 6 months agoA panel of FDA advisers last month found BrainStorm’s data unconvincing. The company now says a...
Q2 2023 Brainstorm Cell Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 8 months agoParticipants Chaim Lebovits; President & CEO; Brainstorm Cell Therapeutics Inc. Stacy Lindborg; Co-CEO; Brainstorm Cell Therapeutics Inc. Alla Patlis; Interim CFO; Brainstorm Cell Therapeutics ...
FDA staff reviewers raise concerns over BrainStorm Cell's ALS therapy (Sept 25)
Reuters via Yahoo News· 7 months agoThe U.S. Food and Drug Administration's staff reviewers raised concerns on Monday over the safety...
Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More
Zacks via Yahoo Finance· 1 year agoDrug approvals and other regulatory news are in focus in the biotech sector. Updates on booster...
US FDA panel votes against BrainStorm's ALS therapy over effectiveness concern
Reuters via AOL· 7 months ago(Reuters) -Advisers to the U.S. health regulator on Wednesday voted against BrainStorm Cell Therapeutics' therapy for a rare and fatal neurodegenerative disease called amyotrophic lateral sclerosis ...